Navigation Links
Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement
Date:8/24/2011

NEWTOWN SQUARE, Pa., Aug. 24, 2011 /PRNewswire/ -- Kibow Biotech, Inc. today announced that it has renewed its exclusive worldwide licensing and marketing agreement with the current licensing partner specializing in animal health. The agreement concerns "Azodyl™," a patented, 100% natural, probiotic dietary supplement indicated for the reduction of azotemia in dogs and cats with moderate to severe renal failure. Developed by Kibow, Azodyl™ has been successfully marketed and sold mainly in USA and Canada since July 2006.

Kibow intends to utilize a major portion of the $2.4 million funding secured for testing a similar, patented, probiotic dietary supplement intended for human consumption. This flagship product, known as "Kibow Biotics™," is targeted towards kidney health and helps improve the quality of life in chronic kidney failure (CKF) patients who also adhere to their routine standardized care of treatment for their pre-existing medical conditions.

Kibow's human clinical trials, involving dialysis and pre-dialysis patients, have already been initiated at Thomas Jefferson University, Philadelphia, PA and at Downstate Medical Center/Kings County Hospitals, State University of New York (SUNY), Brooklyn, NY. Another trial, to be conducted at Mayo clinic, Rochester, MN is soon to begin.

About kidney failure in companion animals:

A leading cause of death among geriatric cats and dogs, "kidney failure" or "renal failure" refers to persistent azotemia, a build-up of uremic toxins in the blood, usually caused by a loss of nephron function in the kidneys.

About Kibow Biotech:

Kibow Biotech, Inc. is a 13-year-old R&D biotechnology company, having its operations in Newtown Square, PA, USA. The company's mission to find a simple, convenient and cost-effective worldwide solution for people experiencing kidney function problems. The company's flagship product is called "Kibow(R) Biotics," an orally consumable, enteric-coated gel cap product formulation that is composed of food-grade microbes ("Probiotics") which metabolize the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. The purpose of this non-drug dietary supplement product is to help maintain a healthy kidney function for people in need of alternative or complementary Over The Counter (OTC) products.

For more information: Dr. N. Ranganathan, Ph.D., Phone: 610 353-5130, http://www.kibowbiotech.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Kibow Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function
2. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
3. Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World
4. Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health
5. Institutional Review Board Approval Obtained for Study of Kibow(R) Biotics in Dialysis Patients with End-stage Chronic Kidney Disease
6. Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc.
7. ALS Therapy Development Institute, the Worlds Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
8. Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology
9. Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech, Inc. Sales in Emerging Markets
10. For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
11. For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
Breaking Biology Technology:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
Breaking Biology News(10 mins):